 |
인쇄하기
취소
|
Celltrion awaits market authorization of Remsima from 52 countries
Celltrion, a local biopharmaceutical company, said Monday that it has awaited approval of Remsima from 52 countries as well as the European Medicines Agency (EMA).
Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.
By the end of this year, it hopes to win approval for the drug from around 20 countries.
In the case of Rem...
Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.
By the end of this year, it hopes to win approval for the drug from around 20 countries.
In the case of Rem...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.